Innovation in Health and Care

Helping policy and other decisionmakers understand how to use innovation to manage global healthcare burdens and improve innovation initiatives in the healthcare system

Featured initiative

Navigating and improving healthcare innovation, industry and policy
RAND Europe helps decisionmakers navigate the changing societal, scientific and technological landscape to identify solutions that positively impact the health of populations and healthcare systems globally.

Research, commentary, and events

Project
New insights into the medical use of cannabis
17 May 2022

Researchers are examining the latest developments and available evidence concerning the medical use of cannabis and cannabinoids for the European Monitoring Centre for Drugs and Drug Addiction.
Project
The impact of predictive genetic tests on the insurance industry
08 Apr 2022

Researchers developed a framework for evaluating the potential effects of predictive genetic tests on the UK insurance industry. The framework provides a transparent approach for evaluating whether a specific condition for which a test is available could impact the insurance industry and understanding the key factors that influence this.
Project
Diagnosis, treatment and management of central diabetes insipidus
07 Mar 2022

RAND Europe was commissioned by Ferring Pharmaceuticals to look at care pathways for patients with CDI. The research focused on identifying the factors that influence the diagnosis, treatment and management of patients with CDI, as well as areas to consider that may improve the quality of care that patients receive, and patient outcomes.
Project
Evaluating the progress and impacts of the COG-UK consortium
15 Feb 2022

An evaluation of the COVID-19 Genomics UK (COG-UK) consortium finds that it has made a significant and valuable contribution to the UK's public health genomics landscape, but its legacy will depend on decision makers' abilities to maintain momentum, ensure adequate governance, and other factors.
Project
The impact of predictive genetic tests on the insurance industry
03 Feb 2022

Researchers developed a framework for evaluating the potential effects of predictive genetic tests on the UK insurance industry. The framework provides a transparent approach for evaluating whether a specific condition for which a test is available could impact the insurance industry and understanding the key factors that influence this.
Project
Understanding industry contributions to the fight against antimicrobial resistance
01 Feb 2022

The AMR Industry Alliance brings together over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations in the fight against AMR. RAND Europe assessed the progress of AMRIA members in contributing to tackling AMR and found they are making a difference on diverse fronts.
Project
The impact of respiratory syncytial virus on the NHS, society and economy in the UK
04 Jan 2022

Researchers are carrying out a rapid evidence assessment and modelling and estimating the wider societal and economic burden of RSV in the UK.
Project
Assessing EHR for infectious disease surveillance, prevention and control
10 Dec 2021

Electronic health records (EHR) data could greatly help infectious disease surveillance, but their use varies across Europe. Researchers mapped EHR use to assess the feasibility of using EHR data for infectious disease surveillance.
Report
The potential socio-economic impact of telemedicine in Canada
06 Dec 2021

RAND Europe researchers examined the potential impact in Canada of continued, long-term use of telemedicine, which can include the use of 'smart' devices to conduct medical tests, the digital storage and sharing of medical records, and real-time tele-consultations between healthcare providers and patients.
Research Brief
Greater telemedicine adoption in Canada could offer economic and social benefits
06 Dec 2021

Alongside the benefits from tools such as telemonitoring and digital health records, researchers found that widespread use of teleconsultations could lead to significant benefits for Canadian patients, the Canadian economy and wider Canadian society.
Commentary
What Are the Practical Considerations for Outcome-Based Payment in the NHS?
02 Dec 2021

Uncertainty can surround the effectiveness or cost-effectiveness of a new medicine, making it difficult to agree on a medicine's price. One solution to avoid unduly delaying or restricting patients' access is to link the medicine's price to the outcomes it produces in a patient. Despite some barriers, outcome-based payment could offer a “win” for patients, the NHS, and industry.
Project
Assessing POCT for infectious disease surveillance, prevention and control
02 Dec 2021

Researchers examined the availability of point-of-care testing (POCT) devices to diagnose 56 communicable diseases and related health issues under EU surveillance — not including COVID-19 — and mapped trends in the use of POCT in Europe.
Project
Making outcome-based payment a reality in the NHS: Phase 2
23 Nov 2021

To prepare for the implementation of a pilot scheme to pay for cancer drugs based on achieved outcomes, researchers addressed issues identified in the first phase of research, such as the quality and completeness of real-world data on key patient outcomes.
Project
The impact of antimicrobial resistance on modern medicine
30 Sep 2021

Most research on antimicrobial resistance (AMR) focuses on its effects on communicable diseases. But AMR can result in a wide variety of negative outcomes for patients with non-communicable health conditions and/or who are exposed to certain healthcare services.
Commentary
Fintech's Role in Reducing Disparities and Financial Barriers to Health Care Access
26 Jul 2021

Given the growing pressures on health care systems globally and the need for innovative approaches to financing health care, the time may be ripe to develop a robust evidence base and share learning on fintech-enabled approaches that could support universal health coverage agendas and healthier and more stable societies.